42nd Annual Miami Breast Cancer Conference® - Abstracts

home / journals / mbcc-suppl / 42nd-annual-miami-breast-cancer-conference---abstracts
39 Development and Validation of a Questionnaire to Assess Motivation and Satisfaction in Mastectomy Patients With or Without Reconstruction

39 Development and Validation of a Questionnaire to Assess Motivation and Satisfaction in Mastectomy Patients With or Without Reconstruction

Eleni Kohilakis;Evan Rothchild;Maya Rosen;Emma Bentley-Hicks;Alessandra Taboada;Maureen McEvoy
June 1st 2025
ArticleMultidisciplinary Specialties
40 Frequency of Documented IHC Score in Patients With HER2-Negative Breast Cancer in the US: An Observational Study Using Guardian Research Network Data

40 Frequency of Documented IHC Score in Patients With HER2-Negative Breast Cancer in the US: An Observational Study Using Guardian Research Network Data

Clara Lam;Zakiya Haji-Noor;Simon Collin;Lisa Okazaki;Simone T. Sredni;Miriam Haviland;Angel Valladares;Caroline Tai;Joseph Imperato
May 31st 2025
ArticleMultidisciplinary Specialties
41 Provider Preferences and Practices in Testing and Reporting HER2 Immunohistochemistry in Patients With Breast Cancer: A Survey and Interview Study Among US Pathologists and Oncologists

41 Provider Preferences and Practices in Testing and Reporting HER2 Immunohistochemistry in Patients With Breast Cancer: A Survey and Interview Study Among US Pathologists and Oncologists

Clara Lam;Zakiya Haji-Noor;Simon Collin;Lisa Okazaki;Simone T. Sredni;Miriam Haviland;Joseph Imperato;Caroline Tai;Angel Valladares
May 30th 2025
ArticleMultidisciplinary Specialties
42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

Ana Sandoval;Joyce A. O’Shaughnessy;Astra M. Liepa;Brenda Grimes;Katheryn Moreira;James Roose;Catherine Keane;Sara M. Tolaney, MD, MPH
May 29th 2025
ArticleMedical Oncology
TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy

TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy

Antonio Llombart-Cussac;José Manuel Pérez-García;Elena Lopez-Miranda;Rui Rui Zhang;Miguel Sampayo-Cordero;Juliana Carvalho-Santos;Olga Boix;Marta Beltran;Carlos Barrios;Guiseppe Curigliano;Rupert Bartsch;Anne Clair Hardy Bessard;Anna Compagnoni;Kathy Puyana Theall;Thomas Buechele;Tomer Wasserman;Javier Cortés, MD
May 28th 2025
ArticleMedical Oncology
45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

Heather McArthur, MD, MPH;Rebecca Dent, MD;Rina Hui;Yeon Hee Park;Peter Schmid, MD;Jing Wei;Jaime Mejia;Wilbur Pan;Javier Cortés, MD
May 27th 2025
ArticleMedical Oncology
46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study

46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study

Heather McArthur, MD, MPH;Peter A. Fasching;Rebecca Dent, MD;Javier Cortés, MD;Lajos Pusztai, MD, DPhil;Sherko Kuemmel;Carsten Denkert;Yeon Hee Park;Rina Hui;Nadia Harbeck, MD, PhD;Masato Takahashi;Seock-Ah Im;Michael Untch, MD, PhD;Marie-Ange Mouret-Reynier;Theodoros Foukakis;Marta Ferreira;Fatima Cardoso;Yu Ding;Cecilia Pinheiro;Jaime Mejia;Joyce A. O’Shaughnessy;Peter Schmid, MD
May 26th 2025
ArticleMedical Oncology
48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status

48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status

Anushree Iyengar;Sandhya Mehta;Hannah Barman;Nivedita Rangarajan;Sue-Ann Woo;Simone T. Sredni;Rosemarie Di Donato;Safak Simsek;Erinn P. Downs;Aziza Nassar;Darren M. Wilson;Katherine Krieser;Elise Bieri Patzke;Natalie Kyek;Jason Hipp;Tyler Wagner, PhD
May 25th 2025
ArticleMedical Oncology
49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

Katheryn Moreira;Kathryn Hudson;Wambui Gathirua-Mwangi;Zhanglin Lin Cui;Madeline Richey;Brenda Grimes;Jingru Wang;Astra Liepa;Erich Brechtelsbauer;Raisa Volodarsky;Hatem Soliman, MD
May 24th 2025
ArticleMedical Oncology
52 Correlation and Prediction of Complete Pathologic Response Rates and Ki-67 in Patients Receiving Neoadjuvant Immunotherapy for Triple-Negative Breast Cancer

52 Correlation and Prediction of Complete Pathologic Response Rates and Ki-67 in Patients Receiving Neoadjuvant Immunotherapy for Triple-Negative Breast Cancer

Harper Niver;Caroline Lippe;W. Bradford Carter
May 23rd 2025
ArticleMedical Oncology
53 Comparison of Surgical Complications With Direct-to-Implant vs Tissue Expander Reconstruction After Wise Pattern Skin-Sparing Mastectomy

53 Comparison of Surgical Complications With Direct-to-Implant vs Tissue Expander Reconstruction After Wise Pattern Skin-Sparing Mastectomy

Areej Alhumaid;Alexandra Lopez-Aguiar;Kristin E. Rojas;Jessica Crystal;John Oeltjen;Devinder Singh;Susan B. Kesmodel
May 22nd 2025
ArticleSurgical Oncology
54 The Treatment of Breast Cancer With Percutaneous Thermal Ablation: Results of the THERMAC Trial

54 The Treatment of Breast Cancer With Percutaneous Thermal Ablation: Results of the THERMAC Trial

Linda Riks;Sophie Wooldrik;Taco Klem;Gerson Struik
May 21st 2025
ArticleImaging and Radiology
55 Do Genetic Counseling and Testing Affect Rates of Contralateral Prophylactic Mastectomy in Patients Without Clinically Actionable Mutations?

55 Do Genetic Counseling and Testing Affect Rates of Contralateral Prophylactic Mastectomy in Patients Without Clinically Actionable Mutations?

Natalie Garver;Valerie L. Staradub, MD;Christopher Verdone;Kelly Mackessy;Alexandra Haraczy;Lianteng Zhi
May 20th 2025
ArticleSurgical Oncology
56 Paternal vs Maternal Inheritance of a BRCA Mutation: Is There a Difference in Presentation and Stage of Breast Cancer at Diagnosis?

56 Paternal vs Maternal Inheritance of a BRCA Mutation: Is There a Difference in Presentation and Stage of Breast Cancer at Diagnosis?

Erika King;Elisa Port;Borna Mohabbatizadeh;Christina Weltz;Jacquelyn Dillon;Jacquelyn Amenta;Mayuri Jain
May 19th 2025
Article
57 Tumor Morphology Concordance in Multifocal/Multicentric Triple- Negative and HER2+ Breast Cancers

57 Tumor Morphology Concordance in Multifocal/Multicentric Triple- Negative and HER2+ Breast Cancers

Frances Phang;Anna Weiss, MD;Huina Zhang
May 18th 2025
Article
59 Are Choosing Wisely Guidelines Applicable to Patients With a High Ki-67 Proliferation Index and Magee Equation Score?

59 Are Choosing Wisely Guidelines Applicable to Patients With a High Ki-67 Proliferation Index and Magee Equation Score?

Leslie Elmore;Neil Carleton;Michael S. Cowher;Rohit Bhargava;Emilia Diego;Kristin Lupinacci;Meaghan Marley;Qurat Ul Ain Sabih;Atilla Soran, MD, MPH;Jennifer Steiman;Ronald Johnson;Erin Bayley;Priscilla F. Mcauliffe, MD, PhD
May 17th 2025
Article
60 Nipple-Sparing Mastectomy in Patients With BRCA and Other Breast Cancer–Related Gene Mutations

60 Nipple-Sparing Mastectomy in Patients With BRCA and Other Breast Cancer–Related Gene Mutations

Maria de la Torre;Erna Busch-Devereaux;Joyce Au
May 16th 2025
ArticleSurgical Oncology
61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?

61 Can the Use of Tumor Margin Markers for Intraoperative Specimen Radiographs Decrease the Rate of Margin Positivity During Breast Conservation Therapy?

Camila Ortega;Micah Brainerd;Christopher Mamone;Caroline Mangira;Andrew Fenton;Mary Murray
May 15th 2025
Article
63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

63 Intraoperative Radiation and External Beam Radiation After Breast-Conserving Surgery in an Ethnic Minority Population: Patient Reported Outcomes Using BREAST-Q

Sheng Chow;Meredith Shamamian;Susan Laura Jao;Andreina Giron;Jessica Lin;Fardeen Bhimani;Eleni Kohilakis;Caroline Oska;Jana Fox;Sheldon Feldman;Maureen McEvoy
May 14th 2025
ArticleImaging and Radiology
64 A Prospective Study to Accurately Define the Nipple-Ward Margins in Patients Undergoing Lumpectomy for Breast Cancer

64 A Prospective Study to Accurately Define the Nipple-Ward Margins in Patients Undergoing Lumpectomy for Breast Cancer

Susan Laura Jao;Fardeen Bhimani;Arianna Cavalli;Bryan Harmon;Maureen McEvoy;Ethan Ravetch;Michelle Sheckley;Anjuli Gupta;Sheldon Feldman
May 13th 2025
ArticleSurgical Oncology
65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

Allen Gee;Grace Oh;June Lee
May 12th 2025
ArticleSurgical Oncology
67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

Ken Weixing Ho;Nicholas Holford;Rathi Ramakrishnan;Patriek Jurrius;Sarah Pinder;Arnie Purushotham;Daniel Leff
May 11th 2025
ArticleSurgical Oncology
68 Upper Extremity Disability Assessment Following Breast Cancer Surgery Using QuickDASH in an Ethnic Minority Population

68 Upper Extremity Disability Assessment Following Breast Cancer Surgery Using QuickDASH in an Ethnic Minority Population

Arianna Cavalli;Susan Laura Jao;Skylar Harbour;Melissa Rony;Sheldon Feldman;Maureen McEvoy
May 10th 2025
ArticleSurgical Oncology
70 Malignancy Upgrade Rates of Discordant Breast Lesions

70 Malignancy Upgrade Rates of Discordant Breast Lesions

Jacquelyn Dillon;Carolyn Vanek;Jeanne Wu;Grace Van Hyfte;Victoria Collins;Christine Chen;Elisa Port;Jennifer L. Marti
May 9th 2025
ArticleSurgical Oncology
71 Beyond the Surface: Suspicious Nipple Lesions

71 Beyond the Surface: Suspicious Nipple Lesions

Margarita Riojas Barrett;Logan Healy;Neil Farnsworth;Elizabeth Bonefas;Alastair Thompson;Stacey Carter
May 8th 2025
ArticleSurgical Oncology
72 Breast Cancer After Breast Augmentation: A Multicenter Collaborative Study Of Patient Management and Outcomes

72 Breast Cancer After Breast Augmentation: A Multicenter Collaborative Study Of Patient Management and Outcomes

Hudhaifah Shaker;Kristin Manor;Shaneel Shah;Emma Barrett;Megan Bydder;Rajiv Dave;James C. Harvey, MD;Cliona Kirwan;Benjamin Baker
May 7th 2025
ArticleMultidisciplinary Specialties
73 Short- and Long-Term Outcomes in Use of Titanium-Coated Polypropylene Meshes in Immediate Breast Reconstruction: A Cost-Effective and Safe Option?

73 Short- and Long-Term Outcomes in Use of Titanium-Coated Polypropylene Meshes in Immediate Breast Reconstruction: A Cost-Effective and Safe Option?

Hudhaifah Shaker;Eleanor Rees;Ian J Whitehead;Ansar Farooq;Noaman Sarfraz
May 6th 2025
ArticleSurgical Oncology
74 Lessons Learned From a Breast Surgery ERAS Program in an Oncologic Ambulatory Center

74 Lessons Learned From a Breast Surgery ERAS Program in an Oncologic Ambulatory Center

Anoushka Afonso;Joanna Serafin;Tiana Sepahpour;Tracy-Ann Moo;Hanae Tokita
May 5th 2025
ArticleSurgical Oncology
75 Comparing 21-Gene Assay Recurrence Scores Before and After Preoperative Radiation Boost in Patients Enrolled in a Phase 2 Prospective Clinical Trial

75 Comparing 21-Gene Assay Recurrence Scores Before and After Preoperative Radiation Boost in Patients Enrolled in a Phase 2 Prospective Clinical Trial

Firas Eladoumikdachi;Deborah Toppmeyer, MD;Zeinab Abou Yehia;Nisha Ohri;Alison Grann;Maria Kowzun;Lindsay Potdevin;Shicha Kumar;Michele Blackwood;Bruce G. Haffty, MD
May 4th 2025
ArticleImaging and Radiology
76 Electromagnetic Chip Bracketed vs Wire Bracketed Localization in Breast Conserving Surgery

76 Electromagnetic Chip Bracketed vs Wire Bracketed Localization in Breast Conserving Surgery

Carly Farrell;Nicole Harris;Paige Aiello;David Detz;Christine Laronga;Laura Kruper;Melissa Mallory;Susan Hoover;Nazanin Khakpour;John Kiluk;Weihong Sun;Junmin Whiting;Brian Czerniecki;Blaise Mooney;Marie Lee
May 3rd 2025
ArticleSurgical Oncology
12>